Phylogenetic distribution of virulence genes among ESBL-producing uropathogenic escherichia coli isolated from long-term hospitalized patients

Journal of Clinical and Diagnostic Research

Volumn 9, Issue 7, 2015, Pages

  Zhao, Ruike ^a   Shi, Jinfang ^a   Shen, Yimin ^a   Li, Yanmeng ^a   Han, Qingzhen ^a   Zhang, Xianfeng ^a   Gu, Guohao ^a   Xu, Jie ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

ESBL; Phylogenetic groups; Resistance; UPEC; Virulence

Indexed keywords

AMIKACIN; AMPICILLIN; BETA LACTAMASE CTX M; CEFAZOLIN; CEFEPIME; CEFOPERAZONE; CEFOPERAZONE PLUS SULBACTAM; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENOMIC DNA; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CTM M GENE; DISK DIFFUSION; DNA ISOLATION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; GENOTYPE; HOSPITAL PATIENT; HUMAN; NONHUMAN; OXA GENE; PHYLOGENY; POLYMERASE CHAIN REACTION; PREVALENCE; SHV GENE; TEM GENE; TERTIARY CARE CENTER; UROPATHOGENIC ESCHERICHIA COLI;

ESCHERICHIA COLI;

EID: 84935135277     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2015/13234.6157     Document Type: Article

References (30)

1. Toval F, Köhler CD, Vogel U, Wagenlehner F, Mellmann A, Fruth A, et al. Characterization of Escherichia coli isolates from hospital inpatients or outpatients with urinary tract infection. J Clin Microbiol. 2014;52(2):407-18.
2. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42(5):657-68.
3. Heffernan HM, Woodhouse RE, Pope CE, Blackmore TK. Prevalence and types of extended-spectrum β-lactamases among urinary Escherichia coli and Klebsiella spp. in New Zealand. Int J Antimicrob Ag. 2009;34(6):544-49.
4. Yu Y, Ji S, Chen Y, Zhou W, Wei Z, Li L, et al. Resistance of strains producing extended-spectrum β-lactamases and genotype distribution in China. J Infection. 2007;54(1):53-57.
5. Chong Y, Yakushiji H, Ito Y, Kamimura T. Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a long-term study from Japan. Eur J Clin Microbiol. 2011;30(1):83-7.
6. Kaper JB, Nataro JP, Mobley HL. Pathogenic escherichia coli. Nat Rev Microbiol. 2004;2(2):123-40.
7. Pitout JD. Extraintestinal pathogenic Escherichia coli: a combination of virulence with antibiotic resistance. Frontiers in Microb. 2012;3:e00009.
8. Köhler CD, Dobrindt U. What defines extraintestinal pathogenic Escherichia coli? Int J Med Microbiol. 2011;301(8):642-47.
9. Le Bouguénec C. Adhesins and invasins of pathogenic Escherichia coli. Int J Med Microbiol. 2005;295(6):471-78.
10. Los FC, Randis TM, Aroian RV, Ratner AJ. Role of pore-forming toxins in bacterial infectious diseases. Microbiol Mol Biol R. 2013;77(2):173-207.
11. Clermont O, Bonacorsi S, Bingen E. Rapid and Simple Determination of theEscherichia coli Phylogenetic Group. Appl. Environ. Microb. 2000;66(10): 4555-58.
12. Lim KT, Yeo CC, Yasin RM, Balan G, Thong KL. Characterization of multidrugresistant and extended-spectrum β-lactamase-producing Klebsiella pneumoniae strains from Malaysian hospitals. J. Med. Microbiol. 2009;58(11):1463-69.
13. Johnson JR, Kuskowski MA, Owens K, Gajewski A, Winokur PL. Phylogenetic origin and virulence genotype in relation to resistance to fluoroquinolones and/ or extended-spectrum cephalosporins and cephamycins among Escherichia coli isolates from animals and humans. J Infect Dis. 2003;188(5):759-68.
14. Dormanesh B, Dehkordi FS, Hosseini S, Momtaz H, Mirnejad R, Hoseini MJ, et al. Virulence Factors and O-Serogroups Profiles of Uropathogenic Escherichia Coli Isolated from Iranian Pediatric Patients. Iranian Red Crescent medical J. 2014;16(2):e14627.
15. Asadi S, Kargar M, Solhjoo K, Najafi A, Ghorbani-Dalini S. The Association of Virulence Determinants of Uropathogenic Escherichia coli With Antibiotic Resistance. Jundishapur J Microbiol. 2014;7(5):e9936.
16. Tramuta C, Robino P, Nucera D, Salvarani S, Banche G, Malabaila A, et al. Molecular characterization and antimicrobial resistance of faecal and urinary Escherichia coli isolated from dogs and humans in Italy. Veterinaria Italiana. 2014;50(1):23-30.
17. Sabaté M, Moreno E, Perez T, Andreu A, Prats G. Pathogenicity island markers in commensal and uropathogenic Escherichia coli isolates. Clinical Microbiology and Infection. 2006;12(9):880-86.
18. Derakhshandeh A, Firouzi R, Motamedifar M, Motamedi Boroojeni A, Bahadori M, Arabshahi S, et al. Distribution of virulence genes and multiple drug-resistant patterns amongst different phylogenetic groups of uropathogenic Escherichia coli isolated from patients with urinary tract infection. Lett Appl Microbiol. 2015;60(2):148-54.
19. Goyal A, Prasad K, Prasad A, Gupta S, Ghoshal U, Ayyagari A. Extended spectrum β-lactamases in Escherichia coli & Klebsiella pneumoniae & associated risk factors. Indian J Med Res. 2009;695-700.
20. Al-Zarouni M, Senok A, Rashid F, Al-Jesmi SM, Panigrahi D. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamaseproducing Enterobacteriaceae in the United Arab Emirates. Med Prin Pract. 2008;17(1):32-36.
21. Maina D, Makau P, Nyerere A, Revathi G. Antimicrobial resistance patterns in extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae isolates in a private tertiary hospital, Kenya. Microbiol. Discovery. 2013;1(1):5.
22. Chakraborty A, Adhikari P, Shenoy S, Saralaya V. Clinical significance and phylogenetic background of extended spectrum β-lactamase producing Escherichia coli isolates from extra-intestinal infections. J Infect Public Health. 2014;
23. Pournaras S, Ikonomidis A, Kristo I, Tsakris A, Maniatis AN. CTX-M enzymes are the most common extended-spectrum β-lactamases among Escherichia coli in a tertiary Greek hospital. J. Antimicrob. Chemoth. 2004;54(2):574-75.
24. Radice M, Power P, Di Conza J, Gutkind G. Early dissemination of CTX-Mderived enzymes in South America. Antimicrob Agents Ch. 2002;46(2):602-4.
25. Abdi HA, Rashki A. Comparison of Virulence Factors Distribution in Uropathogenic E. coli Isolates From Phylogenetic Groups B2 and D. Int J Enteric Pathog. 2014;2(4):e21725.
26. Rodríguez-Baño J, Mingorance J, Fernández-Romero N, Serrano L, López-Cerero L, Pascual A, et al. Virulence profiles of bacteremic extended-spectrum β-lactamase-producing Escherichia coli: association with epidemiological and clinical features. PloS one. 2012;7(9):e44238.
27. Johnson JR, Delavari P, Kuskowski M, Stell AL. Phylogenetic distribution of extraintestinal virulence-associated traits in Escherichia coli. J Infect Dis. 2001;183(1):78-88.
28. Ramos N, Saayman ML, Chapman T, Tucker J, Smith H, Faoagali J, et al. Genetic relatedness and virulence gene profiles of Escherichia coli strains isolated from septicaemic and uroseptic patients. Eur J Clin Microbiol. 2010;29(1):15-23.
29. Lee S, Yu JK, Park K, Oh EJ, Kim SY, Park YJ. Phylogenetic groups and virulence factors in pathogenic and commensal strains of Escherichia coli and their association with blaCTX-M. Ann Clin Lab Sci. 2010;40(4):361-67.
30. Lillo J, Pai K, Balode A, Makarova M, Huik K, Kõljalg S, et al. Differences in Extended-Spectrum Beta-Lactamase Producing Escherichia coli Virulence Factor Genes in the Baltic Sea Region. Biomed Res Int. 2014;e427254.